CNBX Pharmaceuticals Reports Zero Revenue and Significant Losses for Nine Months Ended May 31, 2025

CNBX Pharmaceuticals Inc. reported its financial results for the three and nine months ended May 31, 2025, revealing a continued lack of revenue generation, with total revenues remaining at $0 for both periods. This marks a significant decline compared to the $130,074 in revenue reported for the same nine-month period in 2024. The company attributed this decrease to a reduction in operational activities, which has also impacted its overall financial performance.

Operating expenses for the three months ended May 31, 2025, were $40,380, a decrease of approximately 73% from $152,278 in the same period last year. For the nine months ended May 31, 2025, total operating expenses were reported at $141,960, down from $660,680 in the prior year, reflecting a reduction of $518,720. The decrease in expenses was primarily due to lower general administrative costs and a significant reduction in research and development expenditures, which fell from $268,722 to $0 in the current period. The net loss for the three months was $59,727, compared to a loss of $130,632 in the previous year, while the nine-month net loss was $163,867, down from $634,614.

In terms of strategic developments, CNBX Pharmaceuticals has focused on advancing its drug candidate RCC-33, aimed at treating colorectal cancer. The company plans to initiate Phase I/II clinical trials in 2025. Additionally, the company has seen a notable increase in its common stock, with 61,400,000 shares issued due to the conversion of a loan, raising a total of $106,442. This increase in shares reflects a strategic move to bolster its capital structure amid ongoing financial challenges.

Operationally, CNBX Pharmaceuticals reported a cash balance of $13,648 as of May 31, 2025, down from $26,416 at the end of the previous fiscal year. The company has indicated that it expects to incur at least $1,000,000 in expenses over the next twelve months, primarily for general and administrative costs, as well as research and development. The company has acknowledged the need for additional financing to sustain its operations, highlighting the uncertainty surrounding its ability to continue as a going concern.

Looking ahead, CNBX Pharmaceuticals faces significant challenges in securing the necessary capital to support its operations and clinical development plans. The company has not established any current arrangements for additional funding and has expressed concerns regarding its ability to generate revenue in the near future. The management's forward-looking statements emphasize the importance of attracting investment and maintaining operational viability as the company navigates its financial landscape.